secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001628280-25-009619
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion FY24 revenue $332.3M (+186% Y/Y); net loss narrows to $51.7M from $209.2M
--------------------------------------------------------------------------------

- FY24 total revenue $332.3M (+186% Y/Y); Q4 revenue $69.1M (+114% Y/Y).
- U.S. net product revenue FY24 $115.7M (+48% Y/Y); Q4 $31.6M (+52% Y/Y).
- FY24 net loss $51.7M ($0.28/sh) vs $209.2M ($2.03/sh) in 2023; Q4 net loss $21.3M ($0.11/sh).
- Announced development of two triple combination products with bempedoic acid.
- Strengthened balance sheet: $304.7M from OMERS royalty deal; repaid $210M convertible debt; cash $144.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025009619/0001628280-25-009619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025009619/espr-20250304.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-009619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer